Table 2.
Patient demographics
| Characteristics | Resolution of hematuria (n = 11) | Persistent hematuria (n = 11) | p value |
|---|---|---|---|
| Age, years | 75 (59–85) | 75 (54–87) | 0.7421 |
| BMI, kg/m2 | 28.3 (22.8–38.6) | 26.6 (21.7–31.1) | 0.2541 |
| RTOG grade of morbidity from hematuria | 3 (2–4; mean 3.1) | 4 (3–4; mean 3.7) | 0.0261 |
| Number of transfusions, U | 0 (0–5; mean 1.4) | 4 (0–8; mean 3.3) | 0.0621 |
| Smoking history, pack/years | 11 (0–148) | 30 (0–100) | 0.3941 |
| Time from radiation treatment to HBO therapy, years | 4 (1–16) | 3 (1–17) | |
| Follow-up after HBO, years | 1.88 (0.35–13.6) | 3.01 (1.19–10.9) | 0.1781 |
| PSA at biopsy, ng/ml | 7.4 (2–17) | 7.5 (2–54) | |
| Amount of radiation received, cGy | 6,850 (6,600–7,800) | 7,010 (6,600–7,800) | 0.6351 |
| Ethnicity | 0.6702 | ||
| White | 7 (63.6%) | 5 (45.5%) | |
| Black | 4 (36.4%) | 6 (54.5%) | |
| Anticoagulation (Coumadin therapy) | 3 (27.3%) | 1 (9.1%) | 0.3882 |
| Gleason | 0.5872 | ||
| ≤6 | 7 (63.6%) | 6 (54.5%) | |
| ≥7 | 2 (18.2%) | 3 (27.3%) | |
| Upper tract urinary diversion | 0 | 5 (45%) | 0.0352 |
| Hormonal therapy at time of HBO | 2 (18.2%) | 2 (18.2%) | 1.0002 |
| Timing of radiation | |||
| Primary radiation therapy | 8 (72.7%) | 6 (36.4%) | 0.6942 |
| Adjuvant radiation therapy | 3 (27.3%) | 5 (45.5%) |
Values are expressed as median (range) unless otherwise indicated.
1
Mann-Whitney test.
2
Fisher’s exact test.